Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds

• DOI: 10.1056/evidoa2400147
• Publication Date: 2024-09-01T09:00:17Z
• Authors: Martin Benedikt; Abderrahim Oulhaj; Ursula Rohrer; Martin Manninger; Norbert J. Tripolt; Peter N. Pferschy; Faisal Aziz; Markus Wallner; Ewald Kolesnik; Marianne Gwechenb...; Martin Martinek; Michael Nürnberg; Franz Xaver Roith...; Clemens Steinwender; Johannes Widkal; Simon Leiter; Andreas Zirlik; Markus Stühlinger; Daniel Scherr; Harald Sourij; Dirk von Lewinski

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have beneficial pleiotropic effects, contributing to improved cardiovascular and renal outcomes for patients with without diabetes. The impact of SGLT2is on arrhythmic burden remains largely unexplored through randomized trials.